|
|
Do the initial serum level changes of sCD26 have ability to predict successful treatment with IFN-alpha among naïve chronic hepatitis B patients?
|
|
Speaker:
|
Mostafa Alavi-Moghaddam
|
|
Author:
|
M. Alavi-Moghaddam1*, S.M. Alavian2, S.H. Aalaei-Andabili2
|
|
Affiliation:
|
1Research Institute of Gastroenterology and Liver Diseases, Shahid Beheshti University M.C., 2Research Center for Gastroenterology and Liver Disease (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran. *mosalavi@yahoo.com
|
Introduction: Hepatitis B is a major health problem with serious consequences. In hepatitis B treatment host cellular immune responses have a determinant role and T helper cells are the main active members of immune system against virological infection. The aims of this study are to investigate response rate of patients to INF-Alpha therapy and evaluation of sCD26 and sCD30 roles as presenters of T cells activities in predicting the outcome of therapy in chronic hepatitis B patients.
Methods and materials: Fifty three chronic hepatitis B patients received IFN-9 MU S.C three times weekly for 24 weeks, and were followed up for 24 weeks. Serum levels of sCD26 and sCD30, before, 1 and 3 months after treatment commencement were evaluated in 53 chronic hepatitis B patients and 30 healthy individuals as control group.
Results: Normal level of ALT was seen in 64.1% (34/53) of patients and undetectable DNA was observed in 39.6% (21 out of 53) of them. Finally, 33.9% (18/53) of patients obtained sustain virological response. CD26 levels changes was correlated with response to treatment and significantly (p < 0.001) increased during first 3 months of treatment among patients with successful response to therapy.
Conclusion: Interferon is an effective and safe treatment for chronic hepatitis B patients and sCD26 serum level changes might be useful in predicting the outcome of therapy in naïve chronic hepatitis B patients undergoing treatment with IFN-, as it can help clinicians for withdrawing non-responder patients for prevention of adverse events and economical burden.
|
